“Out of graduate school, Dr. Mohit Jain (co-founder and CEO of Sapient, but a university professor at the time) approached me with a fascinating problem. He had access to a biobank of human samples that, with current technology, would take the better part of a decade to analyze and wanted to know if I could build a pipeline that would allow them to be analyzed in under a year. This development cycle became the basis of the technology that Sapient was founded on.”
Jeramie Watrous, PhD, Co-Founder and Head of Analytical R&D at Sapient, recently sat down with Authority Magazine for an interview in their “The Future is Now” series showcasing cutting-edge technological breakthroughs and the people behind them. He shares personal insights into his career journey as an Analytical Chemist, lessons he’s learned in co-founding a company, and how the ever-growing need within the scientific community to allow for population-scale studies drove development of Sapient’s next-generation, mass spectrometry-based rLC-MS technologies.
Click here to read the full article!
“Out of graduate school, Dr. Mohit Jain (co-founder and CEO of Sapient, but a university professor at the time) approached me with a fascinating problem. He had access to a biobank of human samples that, with current technology, would take the better part of a decade to analyze and wanted… Read More
Biocom LifeLines Magazine Feature: “Illuminating unknowns in the dynamic interplay of genetics, environment, and disease”
Biocom California recently asked Sapient to contribute an article for its Lifelines Magazine, a forum sharing insights and innovations that are leading the way for life science. We discuss why discovery of dynamic, non-genetic biomarkers is needed to elucidate still-unknown contributors and causes of disease, and… Read More
Technology Networks’ Anna MacDonald sat down with Sapient’s Dr. Mo Jain for this Industry Insights piece to discuss the importance of improving biomarker discovery and how next-generation mass spectrometry (MS)-based systems can help to fill the current gap in biomarker technologies. Read an excerpt from the… Read More
Biocompare recently spoke to a panel of experts, including Sapient’s CEO and Founder, Dr. Mo Jain, to get their takes on the challenges and opportunities of using mass spectrometry for biomarker discovery and research. Dr. Jain shares his perspectives on how technological advances in mass spectrometry are “releasing the brakes”… Read More
Sapient recently contributed a piece to Fierce Pharma discussing the new biological and disease insights that small molecule biomarkers can bring to improve drug development success – and how next-generation mass spectrometry is enabling their discovery on an entirely new scale. Excerpt: Dynamic organ physiology, inter-organ communication, host-disease interactions, and… Read More
Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital immune response research for COVID-19 and other autoimmune and inflammation-associated diseases. Cedars-Sinai’s press release highlights key study findings now published in JAMA Network Open on COVID-19 infection awareness rates, indicating… Read More
“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and measure of more than 11,000 circulating small molecule biomarkers – including thousands of yet uncharacterized factors – in a human biosample in less than one… Read More